EC Approves BMS’ Nivolumab SC Formulation for Solid Tumours

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union

EC approves BMS’ nivolumab SC formulation for solid tumours

The EC has granted approval for the new subcutaneous (SC) formulation of Bristol Myers Squibb’s (BMS) Opdivo (nivolumab)

Subcutaneous nivolumab approved in EU, Canada for solid tumors

The approvals are supported by findings from the phase 3 CheckMate-67T trial.

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications